Real-World Treatment Duration With First-line Enfortumab Vedotin Plus Pembrolizumab for Advanced Urothelial Cancer: A National Electronic Health Record Study

Clinical Genitourinary Cancer · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles